Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Biology
  • View Item
  • Home
  • ICR Divisions
  • Cancer Biology
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Thumbnail
View/Open
Published version (1.185Mb)
Publication Date
2016-10-06
ICR Author
Hall, Emma
Harrington, Kevin
Emson, Marie
Morden, James Peter
Author
Petkar, I
Rooney, K
Roe, JW
Patterson, JM
Bernstein, D
Tyler, JM
Emson, MA
Morden, JP
Mertens, K
Miles, E
Beasley, M
Roques, T
Bhide, SA
Newbold, KL
Harrington, KJ
Hall, E
Nutting, CM
Type
Journal Article
Metadata
Show full item record
Abstract
Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of critical swallowing structures such as the pharyngeal constrictor muscle and supraglottic larynx can translate to better functional outcomes. However, there are no current randomised studies to confirm the benefits of such swallow sparing strategies. The aim of Dysphagia/Aspiration at risk structures (DARS) trial is to determine whether reducing the dose to the pharyngeal constrictors with dysphagia-optimised intensity- modulated radiotherapy (Do-IMRT) will lead to an improvement in long- term swallowing function without having any detrimental impact on disease-specific survival outcomes.The DARS trial (CRUK/14/014) is a phase III multicentre randomised controlled trial (RCT) for patients undergoing primary (chemo) radiotherapy for T1-4, N0-3, M0 pharyngeal cancers. Patients will be randomised (1:1 ratio) to either standard IMRT (S-IMRT) or Do-IMRT. Radiotherapy doses will be the same in both groups; however in patients allocated to Do-IMRT, irradiation of the pharyngeal musculature will be reduced by delivering IMRT identifying the pharyngeal muscles as organs at risk. The primary endpoint of the trial is the difference in the mean MD Anderson Dysphagia Inventory (MDADI) composite score, a patient-reported outcome, measured at 12 months post radiotherapy. Secondary endpoints include prospective and longitudinal evaluation of swallow outcomes incorporating a range of subjective and objective assessments, quality of life measures, loco-regional control and overall survival. Patients and speech and language therapists (SLTs) will both be blinded to treatment allocation arm to minimise outcome-reporting bias.DARS is the first RCT investigating the effect of swallow sparing strategies on improving long-term swallowing outcomes in pharyngeal cancers. An integral part of the study is the multidimensional approach to swallowing assessment, providing robust data for the standardisation of future swallow outcome measures. A translational sub- study, which may lead to the development of future predictive and prognostic biomarkers, is also planned.This study is registered with the International Standard Randomised Controlled Trial register, ISRCTN25458988 (04/01/2016).
URL
https://repository.icr.ac.uk/handle/internal/182
Collections
  • Cancer Biology
  • Clinical Studies
  • Radiotherapy and Imaging
Research team
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Targeted Therapy
Language
eng
Date accepted
2016-09-26
License start date
2016-10-06
Citation
BMC cancer, 2016, 16 (1), pp. 770 - ?

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.